FOOD AND DRUG ADMINISTRATION 
Center for Drug Evaluation and Research 

Endocrinologic and Metabolic Drugs Advisory Committee Meeting  

FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center       

(Room 1503), 10903 New Hampshire Avenue, Silver Spring, MD  

October 16, 2013 

MEETING ROSTER 

 

 

 

ACTING DESIGNATED FEDERAL OFFICER 
(NON-VOTING) 
 
Stephanie L. Begansky, PharmD  
Division of Advisory Committee and Consultant Management 
Office of Executive Programs 
Center for Drug Evaluation and Research 
 
ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE 
MEMBERS (VOTING) 

 

 
 

Erica H. Brittain, PhD 
Mathematical Statistician 
Biostatistics Research Branch 
National Institute of Allergy and Infectious 
Diseases (NIAID) 
National Institutes of Health (NIH) 
Bethesda, Maryland 

David W. Cooke, MD 
Clinical Director, Division of Pediatric 
Endocrinology 
Director, Pediatric Endocrine Fellowship 
Training Program 
Johns Hopkins University School of 
Medicine 
Baltimore, Maryland 
 
Edward W. Gregg, Ph.D. 
Chief, Epidemiology and Statistics Branch 
Division of Diabetes Translation 
Centers for Disease Control and Prevention 
Atlanta, Georgia 
 
Diana Hallare, MPH 
(Consumer Representative) 
Visalia, California  
 
 
 
 
 

William R. Hiatt, MD, FACP 
Professor of Medicine 
Division of Cardiology 
University of Colorado School of Medicine 
President, Colorado Prevention Center (CPC) 
Clinical Research 
Aurora, Colorado 
 
Ellen W. Seely, MD 
Professor of Medicine 
Harvard Medical School 
Division of Endocrinology, Diabetes and 
Hypertension 
Brigham and Womenâ€™s Hospital 
Boston, Massachusetts 
Robert J. Smith, MD 
(Acting Chairperson) 
Professor of Medicine (Endocrinology) 
Alpert Medical School of Brown University 
Ocean State Research Institute 
Providence Veterans Administration Medical 
Center 
Providence, Rhode Island 
 
 
 
 

 

1 of 2 

FOOD AND DRUG ADMINISTRATION 
Center for Drug Evaluation and Research 

Endocrinologic and Metabolic Drugs Advisory Committee Meeting  

 

 

 

October 16, 2013 

MEETING ROSTER (cont.) 

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE 
MEMBERS (NON-VOTING) 
 
Mads F. Rasmussen, MD, PhD 
(Industry Representative) 
Executive Director 
Clinical Development and Research, Diabetes 
Clinical Development 
Medical and Regulatory Affairs 
Novo Nordisk Inc. 
Princeton, New Jersey 
 
TEMPORARY MEMBERS (VOTING) 
 
Brendan M. Everett, MD, MPH 
Assistant Professor 
Harvard Medical School 
Director General Cardiology Inpatient 
Service 
Cardiovascular and Preventive Medicine 
Brigham and Women's Hospital 
Boston, Massachusetts 
 
Frank Harrell, PhD 
Professor of Biostatistics 
Chair, Department of Biostatistics 
Vanderbilt University School of Medicine 
Nashville, Tennessee 
 
FDA PARTICIPANTS (Non-Voting) 
 
Mary H. Parks, MD 
Deputy Director 
Office of Drug Evaluation II (ODE-II) 
Office of New Drugs (OND), CDER, FDA 
 
Jean-Marc Guettier, MD 
Director (Acting) 
Division of Metabolism and Endocrinology 
Products (DMEP), ODE-II, OND, CDER, 
FDA 
 
 
 

 
 
Pamela McAllister, PhD 
(Patient Representative) 
Research Advocate, Fight Colorectal Cancer 
Alexandria, Virginia  
 
 
Peter W.F. Wilson, MD 
Professor of Medicine 
Emory University 
School of Medicine 
Department of Cardiology 
Atlanta, Georgia 
 
 
 
 
 
Eric Colman, MD 
Deputy Director 
DMEP, ODE-II, OND, CDER, FDA 
 
James P. Smith, MD, MS 
Clinical Team Leader 
DMEP, ODE-II, OND, CDER, FDA 
 
Mary Dunne Roberts, MD 
Clinical Reviewer 
DMEP, ODE-II, OND, CDER, FDA 

2 of 2 

